Metastatic Extrahepatic Cholangiocarcinoma: Clinical Trials

2 trials for Metastatic Extrahepatic Cholangiocarcinoma, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 not yet recruiting, 1 recruiting. 2 Phase 2, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 22Not yet recruiting 1, Recruiting 1
Phase 31Not yet recruiting 1

Follow Metastatic Extrahepatic Cholangiocarcinoma: new trials by email Literature Review of Metastatic Extrahepatic Cholangiocarcinoma trials Research Report on Metastatic Extrahepatic Cholangiocarcinoma

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Testing the Addition of Ivonescimab Combined With Standard Chemotherapy Compared to the Usual Chemotherapy and Immunotherapy Treatment for Patients With Advanced Biliary Tract Cancer
Biospecimen Collection, Cisplatin, Computed Tomography - Locally Advanced Biliary Tract Adenocarcinoma, Locally Advanced Extrahepatic Cholangiocarcinoma
Phase 2 / Phase 3Not yet recruitingECOG-ACRIN Cancer Research Group3362027-01-112026-08-14
Alternating Chemo-immunotherapy and FGFR Inhibitor for FGFR-positive Biliary or Cholangiocarcinoma
Biospecimen Collection, Cisplatin, Computed Tomography - Locally Advanced Ampulla of Vater Carcinoma, Locally Advanced Biliary Tract Carcinoma
Phase 2RecruitingOhio State University Comprehensive Cancer Center292026-11-012026-09-10

Narrower conditions

Cholangiocarcinoma (2)  ·  Gallbladder Neoplasms (1)

Broader conditions

Adenocarcinoma (2)  ·  Carcinoma (2)  ·  Neoplasms (2)  ·  Neoplasms by Histologic Type (2)  ·  Neoplasms, Glandular and Epithelial (2)  ·  Biliary Tract Diseases (1)  ·  Biliary Tract Neoplasms (1)  ·  Digestive System Diseases (1)  ·  Digestive System Neoplasms (1)  ·  Gallbladder Diseases (1)  ·  Neoplasms by Site (1)

Interventions

1,2-diaminocyclohexaneplatinum II citrate (2)  ·  Cisplatin (2)  ·  Disulfides (2)  ·  Gemcitabine (2)  ·  Immunoglobulin G (2)  ·  Magnetic Resonance Spectroscopy (2)  ·  Platinum (2)  ·  Specimen Handling (2)  ·  durvalumab (2)  ·  pembrolizumab (1)  ·  pemigatinib (1)

Sponsors

ECOG-ACRIN Cancer Research Group (1)  ·  Ohio State University Comprehensive Cancer Center (1)

Countries

United States (1)

Top investigators

Deirdre J Cohen (1)  ·  Sameek Roychowdhury, MD, PhD (1)

NIH funding

U10CA180820 (1)